<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03181256</url>
  </required_header>
  <id_info>
    <org_study_id>VICC THO 1730</org_study_id>
    <secondary_id>NCI-2017-00889</secondary_id>
    <secondary_id>CA152662</secondary_id>
    <nct_id>NCT03181256</nct_id>
  </id_info>
  <brief_title>Early Detection of Lung Cancer</brief_title>
  <official_title>Early Detection of Lung Cancer in the Medically Underserved Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research trial studies the long term follow-up for early detection of lung cancer in
      current or former smokers. Following up on smokers by collecting and analyzing specimens in
      the laboratory, performing chest computed tomography (CT) scans, as well as reviewing medical
      records may help doctors detect lung cancer at an earlier stage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To provide screening for lung cancer in an underserved and high risk population for lung
      cancer.

      II. To collect clinical and demographic information and research bio specimens prospectively
      on high risk individuals.

      III. To analyze the association between suspected lung cancer risk factors and outcomes such
      as pre-malignant lesions and diagnosis of lung cancer.

      IV. To identify and validate biomarkers that are associated with lung cancer risk factors and
      premalignant lesions.

      V. To assess the association between patient characteristics and test results to the genetic
      and histological characteristics of lung preinvasive lesions and cancers.

      VI. To describe this high-risk cohort and to identify the patients eligible for future
      clinical trials (e.g. chemoprevention).

      OUTLINE:

      Patients are followed up at 1, 2, 3, 4, and 5 years and undergo collection of sputum, nasal
      epithelium, buccal epithelium, blood, and urine samples. Patients also undergo pulmonary
      function tests, chest CT, and review of medical records.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Candidate biomarkers of risk or of early diagnosis</measure>
    <time_frame>Up to 5 years.</time_frame>
    <description>Will validate the performance of the candidate biomarkers of risk or of early diagnosis.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Screening</arm_group_label>
    <description>Patients are followed up at 1, 2, 3, 4, and 5 years and undergo collection of sputum, nasal epithelium, buccal epithelium, blood, and urine samples. Patients also undergo pulmonary function tests, chest CT, and review of medical records</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of sputum</description>
    <arm_group_label>Screening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen collection</intervention_name>
    <description>Undergo collection of nasal epithelium</description>
    <arm_group_label>Screening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen collection</intervention_name>
    <description>Undergo collection of buccal epithelium</description>
    <arm_group_label>Screening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen collection</intervention_name>
    <description>Undergo collection of blood</description>
    <arm_group_label>Screening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen collection</intervention_name>
    <description>Undergo collection of urine</description>
    <arm_group_label>Screening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary Function Test</intervention_name>
    <description>Undergo pulmonary function test</description>
    <arm_group_label>Screening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography (CT)</intervention_name>
    <description>Undergo chest CT</description>
    <arm_group_label>Screening</arm_group_label>
    <other_name>Undergo chest CT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Screening</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sputum, nasal epithelium, buccal epithelium, blood, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Current or former smokers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current smoker or former smoker, if former smoker participants must have quit smoking
             within the past 15 years

          -  &gt;= 30 pack year of smoking history

          -  Participant is uninsured

        Exclusion Criteria:

          -  History of diagnosis/treatment of lung cancer in the past 2 years

          -  History of head/neck or esophageal cancer in the last 1 year

          -  Inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Pierre Massion, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Information Program</last_name>
    <phone>800-811-8480</phone>
    <email>cip@vanderbilt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VICC Clinical Trials Information Program</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Pierre Massion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Pierre P. Massion, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

